Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06185556 |
TitleCOLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases | 阶段
第二阶段
|
Date Added 2023-12-29 |
地点
荷兰
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06176885 |
TitleEfficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-12-20 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Camrelizumab |
标签
MSS/ MMRp
|
| NCT ID NCT06152523 |
TitleMonalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer | 阶段
第二阶段
|
Date Added 2023-11-30 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Monalizumab/MEDI5257 |
标签
MSI-H/ MMRd
|
| NCT ID NCT06149481 |
Title联合免疫疗法方案的 I/II 期研究：治疗转移性结直肠癌 (mCRC) 的联合免疫疗法方案：SX-682、TriAdeno 疫苗、雷替凡利单抗和 IL-15 激动剂 N-803 (STAR15) | 阶段
Phase 1, Phase 2
|
Date Added 2023-11-29 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
N-803, Retifanlimab, SX-682 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06120127 |
TitlePostoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence | 阶段
第二阶段
|
Date Added 2023-11-07 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Chemotherapy, PD-1 antibody |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06106308 |
TitleStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | 阶段
第二阶段
|
Date Added 2023-10-30 |
地点
Arizona, United States
Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, FOLFIRI, FOLFOX, Onvansertib |
标签
MSS/ MMRp
|
| NCT ID NCT06107413 |
TitleStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | 阶段
第二阶段
|
Date Added 2023-10-30 |
地点
Arizona, United States
Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States 比利时 德国 以色列 日本 大韩民国 西班牙 台湾 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan |
标签
MSS/ MMRp
|
| NCT ID NCT06105021 |
TitlePhase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | 阶段
Phase 1, Phase 2
|
Date Added 2023-10-27 |
地点
California, United States
Connecticut, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
AFNT-211 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06102902 |
TitleTesting the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC | 阶段
第 1 阶段
|
Date Added 2023-10-26 |
地点
California, United States
Kansas, United States Ohio, United States Oklahoma, United States Texas, United States Virginia, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
BET Bromodomain Inhibitor ZEN-3694, encorafenib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06099821 |
TitleKN046联合瑞戈非尼或阿帕替尼治疗对PD-1/PD-L1阻断剂耐药的MSI-H消化系统癌症 | 阶段
第二阶段
|
Date Added 2023-10-25 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
apatinib, KN046, Regorafenib |
标签
MSI-H/ MMRd
|
